News coverage about Steris Plc (NYSE:STE) has trended somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Steris Plc earned a media sentiment score of 0.07 on Accern’s scale. Accern also assigned headlines about the medical equipment provider an impact score of 47.4892356554364 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news headlines that may have effected Accern Sentiment’s rankings:
- Hybrid Operating Room Market Projected To Draw a Healthy Growth of 12.5% by 2027 (abnewswire.com)
- Global Operating Room Management Market to Reach a Value of About US $3,600 Mn over 2017-2022 (sbwire.com)
- Zacks: Analysts Set $100.00 Price Target for Steris Plc (STE) (americanbankingnews.com)
- Stretcher Chair Market Growth Analysis until 2022 (reports.pr-inside.com)
- North America to Offer High Growth Opportunities to Players in Operating Room Management Market During the 2017 – 2022 Timeline (sbwire.com)
A number of research analysts recently issued reports on STE shares. Raymond James Financial, Inc. boosted their price objective on Steris Plc from $95.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, October 16th. KeyCorp reiterated a “buy” rating and set a $91.00 price objective on shares of Steris Plc in a research note on Tuesday, October 17th. Zacks Investment Research downgraded Steris Plc from a “buy” rating to a “hold” rating in a research note on Tuesday, August 22nd. BidaskClub downgraded Steris Plc from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Finally, TD Securities boosted their price objective on Steris Plc from C$14.00 to C$16.00 and gave the company a “buy” rating in a research note on Thursday, November 9th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $77.80.
Steris Plc (NYSE STE) opened at $88.26 on Wednesday. Steris Plc has a 52 week low of $64.37 and a 52 week high of $93.39. The company has a quick ratio of 2.18, a current ratio of 2.80 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $7,444.63, a P/E ratio of 22.56 and a beta of 1.31.
Steris Plc (NYSE:STE) last posted its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $0.94 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.95 by ($0.01). Steris Plc had a return on equity of 11.49% and a net margin of 5.59%. The business had revenue of $634.20 million during the quarter, compared to the consensus estimate of $629.02 million. During the same quarter in the previous year, the company earned $0.89 earnings per share. The company’s revenue for the quarter was down 1.9% compared to the same quarter last year. equities analysts anticipate that Steris Plc will post 4.06 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 20th. Shareholders of record on Wednesday, November 22nd will be paid a $0.31 dividend. The ex-dividend date of this dividend is Tuesday, November 21st. This represents a $1.24 annualized dividend and a yield of 1.40%. Steris Plc’s payout ratio is 73.81%.
In other news, CEO Walter M. Rosebrough, Jr. sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $90.50, for a total transaction of $905,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Michael J. Tokich sold 12,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $89.75, for a total value of $1,077,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 189,072 shares of company stock worth $16,592,553 over the last ninety days. Insiders own 2.55% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was first published by Week Herald and is the sole property of of Week Herald. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://weekherald.com/2017/11/15/steris-plc-ste-receiving-somewhat-favorable-press-coverage-analysis-finds.html.
About Steris Plc
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
Receive News & Ratings for Steris Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris Plc and related companies with MarketBeat.com's FREE daily email newsletter.